CRP and COVID-19: In individuals without COVID-19 or hyperlipidemia but with elevated CRP levels, rosuvastatin was found to decrease the risk of major cardiovascular events by 44% (250), which was attributed to its pleiotropic anti-inflammatory effects (251).